Trials / Terminated
TerminatedNCT00496002
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus
A Multi-Center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Pharmasset · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study are to compare in nucleoside treatment-naïve subjects, the efficacy and safety of clevudine 30 mg once daily versus adefovir 10 mg once daily, each as monotherapy, for 48 weeks and 96 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clevudine | |
| DRUG | Adefovir |
Timeline
- Start date
- 2007-08-01
- First posted
- 2007-07-04
- Last updated
- 2009-04-27
Locations
134 sites across 12 countries: United States, Argentina, Australia, Brazil, Canada, China, Greece, Puerto Rico, Spain, Taiwan, Thailand, United Kingdom
Source: ClinicalTrials.gov record NCT00496002. Inclusion in this directory is not an endorsement.